Evidence map›Paper›PMID 26947602›Full record

Trial reportEuropean urology2016

Exploratory Decision-Tree Modeling of Data from the Randomized REACTT Trial of Tadalafil Versus Placebo to Predict Recovery of Erectile Function After Bilateral Nerve-Sparing Radical Prostatectomy.

Francesco Montorsi, Matthias Oelke, Carsten Henneges, Gerald Brock, Andrea Salonia, Gianluca d'Anzeo, Andrea Rossi, John P Mulhall, Hartwig Büttner

Registry-linked trialOpen access · greenAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in European urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01026818 (A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Effect on Unassisted Erectile Function of the Early Use of Tadalafil 5 mg Once a Day and Tadalafil 20 mg On Demand Treatment for 9 Months in Subjects Undergoing Bilateral Nerve-Sparing Radical Prostatectomy), which is not on this map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01026818 phase4completednot on this map

A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Effect on Unassisted Erectile Function of the Early Use of Tadalafil 5 mg Once a Day and Tadalafil 20 mg On Demand Treatment for 9 Months in Subjects Undergoing Bilateral Nerve-Sparing Radical Prostatectomy

TypeinterventionalSponsorEli Lilly and CompanyRan2009 to 2012Enrolled583ConditionsErectile DysfunctionArmsTadalafil, Placebo
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 28 citations in OpenAlex.

  1. CUAJ is a key partner for academic urology Memories and observations from two Western University old-timers.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Problems in defining sexual dysfunction in prostate cancer patients.International journal of impotence research · 2021
    Article
  7. Review
  8. Review
  9. Erectile Dysfunction: A Primer for in Office Management.Medical sciences (Basel, Switzerland) · 2019
    Review
  10. Postprostatectomy Erectile Dysfunction: A Review.The world journal of men's health · 2016
    Review
  11. PDE-5 inhibitors should be used post radical prostatectomy as erection function rehabilitation? | Opinion: Yes.International braz j urol : official journal of the Brazilian Society of Urology
    Review
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 4 countries.

Francesco MontorsiDepartment of Urology, Vita Salute San Raffaele University, Milan, Italy. Electronic address: napoli.patrizia@hsr.it.
Matthias OelkeDepartment of Urology and Urological Oncology, Hanover Medical School, Hanover, Germany.
Carsten HennegesGlobal Statistical Sciences, EU Statistics, Lilly Deutschland GmbH, Bad Homburg, Germany.
Gerald BrockDepartment of Surgery, Division of Urology, University of Western Ontario, London, Ontario, Canada.
Andrea SaloniaDepartment of Urology, Vita Salute San Raffaele University, Milan, Italy.
Gianluca d'AnzeoTherapeutic Area Men's Health, Eli Lilly SpA, Florence, Italy.
Andrea RossiTherapeutic Area Men's Health, Eli Lilly SpA, Florence, Italy.
John P MulhallMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Hartwig BüttnerBiomedicines BU, Lilly Deutschland GmbH, Bad Homburg, Germany.
Eli Lilly (Italy) · ITVita-Salute San Raffaele University · ITMedizinische Hochschule Hannover · DEMemorial Sloan Kettering Cancer Center · USWestern University · CA

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

backgroundUnderstanding predictors for the recovery of erectile function (EF) after nerve-sparing radical prostatectomy (nsRP) might help clinicians and patients in preoperative counseling and expectation management of EF rehabilitation strategies.

objectiveTo describe the effect of potential predictors on EF recovery after nsRP by post hoc decision-tree modeling of data from A Study of Tadalafil After Radical Prostatectomy (REACTT). DESIGN, SETTING, AND

participantsRandomized double-blind double-dummy placebo-controlled trial in 423 men aged <68 yr with adenocarcinoma of the prostate (Gleason ≤7, normal preoperative EF) who underwent nsRP at 50 centers from nine European countries and Canada.

interventionPostsurgery 1:1:1 randomization to 9-mo double-blind treatment with tadalafil 5mg once a day (OaD), tadalafil 20mg on demand, or placebo, followed by a 6-wk drug-free-washout, and a 3-mo open-label tadalafil OaD treatment. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Three decision-tree models, using the International Index of Erectile Function-Erectile Function (IIEF-EF) domain score at the end of double-blind treatment, washout, and open-label treatment as response variable. Each model evaluated the association between potential predictors: presurgery IIEF domain and IIEF single-item scores, surgical approach, nerve-sparing score (NSS), and postsurgery randomized treatment group. RESULTS AND LIMITATIONS: The first decision-tree model (n=422, intention-to-treat population) identified high presurgery sexual desire (IIEF item 12: ≥3.5 and <3.5) as the key predictor for IIEF-EF at the end of double-blind treatment (mean IIEF-EF: 14.9 and 11.1), followed by high confidence to get and maintain an erection (IIEF item 15: ≥3.5 and <3.5; IIEF-EF: 15.4 and 7.1). For patients meeting these criteria, additional non-IIEF-related predictors included robot-assisted laparoscopic surgery (yes or no; IIEF-EF: 19.3 and 12.6), quality of nerve sparing (NSS: <2.5 and ≥2.5; IIEF-EF: 14.3 and 10.5), and treatment with tadalafil OaD (yes and no; IIEF-EF: 17.6 and 14.3). Additional analyses after washout and open-label treatment identified high presurgery intercourse satisfaction as the key predictor.

conclusionsExploratory decision-tree analyses identified high presurgery sexual desire, confidence, and intercourse satisfaction as key predictors for EF recovery. Patients meeting these criteria might benefit the most from conserving surgery and early postsurgery EF rehabilitation. Strategies for improving EF after surgery should be discussed preoperatively with all patients; this information may support expectation management for functional recovery on an individual patient level. PATIENT SUMMARY: Understanding how patient characteristics and different treatment options affect the recovery of erectile function (EF) after radical surgery for prostate cancer might help physicians select the optimal treatment for their patients. This analysis of data from a clinical trial suggested that high presurgery sexual desire, sexual confidence, and intercourse satisfaction are key factors predicting EF recovery. Patients meeting these criteria might benefit the most from conserving surgery (robot-assisted surgery, perfect nerve sparing) and postsurgery medical rehabilitation of EF.

trial registrationClinicalTrials.gov, NCT01026818.

Indexed as

Decision TreesAdenocarcinomaAgedCoitusDouble-Blind MethodErectile DysfunctionHumansMaleMiddle AgedOrgan Sparing TreatmentsPenile ErectionPhosphodiesterase 5 InhibitorsPreoperative PeriodProstatectomyProstatic NeoplasmsRecovery of FunctionPhosphodiesterase 5 InhibitorsTadalafilClinical trialsDecision-tree analysisErectile dysfunctionNerve-sparing radical prostatectomyPhosphodiesterase type 5 inhibitorsPredictorsProstate cancerRehabilitationTadalafil

Identifiers

PMID26947602
PMCPMC5478190
OpenAlexW2290563936

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.